Human Growth Hormone Biomarker for Cardiovascular Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for stratifying patients at risk for cardiovascular disease for pharmacologic intervention are limited to biomarkers associated with vasoactive or inflammatory activities, and human growth hormone (hGH) has not been previously described in this context, despite elevated levels being associated with increased cardiac event risk.
Innovation Solution
Determining the level of hGH and/or its isoforms in a blood sample and comparing it to a pre-determined threshold to identify vascular risk reduction potential with antihypertensive drugs such as ACE inhibitors, ARBs, Beta-blockers, and statins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional biomarkers (vasoactive or inflammatory) are used for patient stratification, then the stratification method is well-established, but it cannot identify all patients who would benefit from antihypertensive therapy
Solution Approach 1:
The patent changes the biomarker parameter from traditional vasoactive or inflammatory markers to human growth hormone (hGH) levels. This parameter change enables identification of a broader patient population (including those with normal traditional markers) who would benefit from antihypertensive therapy, thereby resolving the contradiction between established methodology and expanded applicability
2Adaptability or versatility
If hGH level determination is added to patient stratification, then more patients can be identified for therapy, but the diagnostic process becomes more complex
Solution Approach 1:
The patent segments the patient population into distinct groups based on hGH levels (elevated vs. normal), allowing targeted therapy recommendations. This segmentation approach simplifies the complex diagnostic process by creating clear, actionable categories rather than requiring continuous assessment of multiple overlapping biomarkers
3Adaptability or versatility
If hGH level determination is added to patient stratification, then more patients can be identified for therapy, but the testing procedure becomes more involved
Solution Approach 1:
The patent uses hGH level measurement as an intermediary biomarker that mediates between traditional risk assessment and therapy selection. This intermediary approach simplifies the overall testing procedure by providing a single, clear indicator that complements rather than replaces existing assessment methods, making the extended diagnostic process more manageable
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
Subject matter of the present invention is a method of determining whether a subject has a vascular risk that can be reduced by blood pressure lowering therapy with antihypertensive drugs (e.g. Angiotensin converting enzyme inhibitor (ACE inhibitor), Angiotensin Receptor Blocker (ARB), Beta-Adrenoreceptor Blocker (Beta-blocker) and/or statins) comprising the steps: • determining the level of hGH, and/or its isoforms in a blood sample of said subject and • comparing the determined level of hGH, and/or its isoforms in said blood sample with a pre-determined threshold and • wherein in case the determined level of hGH, and/or its isoforms is above said pre-determined threshold then the subject is identified as having a vascular risk that can be reduced by blood pressure lowering therapy with antihypertensive drugs (e.g. Angiotensin converting enzyme inhibitor (ACE inhibitor), Angiotensin Receptor Blocker (ARB), Beta-Adrenoreceptor Blocker (Beta-blocker) and/or statins) and wherein in case the determined level of hGH, and/or its isoforms is below said pre-determined threshold then the subject is identified as not having a vascular risk that can be reduced by blood pressure lowering therapy with antihypertensive drugs (e.g. Angiotensin converting enzyme inhibitor (ACE inhibitor), Angiotensin Receptor Blocker (ARB), Beta- Adrenoreceptor Blocker (Beta-blocker) and/or statins).